O-RAN ALLIANCE Announces New Specifications and Demos, First Open Test and Integration Centers and Its June 29 Industry Summit
O-RAN ALLIANCE welcomes stc as its new operator member, building up the world-wide community of 29 mobile network operators committed to deployment of open and intelligent Radio Access Networks (RAN).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210623005961/en/
O-RAN Logical Architecture (Graphic: Business Wire)
33 New or Updated O-RAN Specifications Released since March 2021
On June 17, 2021, the O-RAN ALLIANCE published another 33 specification documents, including 11 new titles. Among others these new specifications include:
- Management interface, timing and synchronization for Transport
- The baseline for Non-Real-Time Radio Intelligent Controller (Non-RT RIC) and Near-Real-Time RIC Architecture and interfaces (E2, A1, F1/X2/Xn)
- Certification and badging guidelines and parts of end-to-end, inter-operability and conformance testing
For more details on the new specifications, please check this O-RAN blog post. To download O-RAN specifications, please proceed to www.o-ran.org/specifications.
First European Open Test and Integration Centers Hosted by Deutsche Telekom and TIM
The O-RAN ALLIANCE approved the first two European Open Test and Integration Centers (OTIC):
- European OTIC in Berlin hosted by Deutsche Telekom
- European OTIC in Torino hosted by TIM
OTICs provide a collaborative, open, and impartial working environment to ensure consistency and quality of testing of O-RAN products and solutions.
“It is great to see the momentum in adoption of O-RAN based solutions,” said Alex Jinsung Choi, COO of the O-RAN ALLIANCE and SVP Technology Strategy & Technology Innovation, Deutsche Telekom. “OTICs will play an important role in managing the complex interoperability scenarios and related integration cost, and accelerate O-RAN product commercialization in large network solutions.”
36 New O-RAN Demonstrations
O-RAN ALLIANCE is excited to announce the release of 36 demos to be showcased at the O-RAN Virtual Exhibition by June 29, 2021. Five of these demos will also be presented at the MWC Barcelona exhibition by:
- Parallel Wireless at Hall 5, Booth 515
- Rohde & Schwarz at Hall 6, Booth B30
- Sageran, presenting 3 demos at Hall 7, Booth 7N50
More companies are presenting their demos in the virtual form: Analog Devices, Arm, Astri, Baicells, Capgemini, China Mobile, CIG, Comba Telecom, H3C, Intel, IS-Wireless, ITRI, Juniper Networks, Keysight, Lenovo, NEC, Netcracker, Nokia, Nvidia, NXP, O-RAN Software Community, Parallel Wireless, Pegatron, Radisys, Rohde & Schwarz, Qualcomm, Sageran, Siemens EDA, TIM, T&W, VIAVI Solutions, WindRiver.
For more details on these demos, please read our blog post.
O-RAN ALLIANCE Industry Summit on June 29, 2021
O-RAN ALLIANCE plans to hold its next Industry Summit on June 29th. The 90 minute live virtual session will provide exclusive insights from top executives that are driving the rapid advances in the O-RAN space. During the panel discussion speakers from AirHop Communications, AT&T, Deutsche Telekom, Facebook, Mavenir, Nokia, Rakuten Mobile, TIM, VIAVI and VMware will share their views on key topics including Open RAN Commercialization, Open RAN Security and Performance. The summit will conclude with a live Q&A where the audience can submit their questions for the panelists. Join the event at www.o-ran.org/events.
About O-RAN ALLIANCE
The O-RAN ALLIANCE is a world-wide community of 300 mobile operators, vendors, and research & academic institutions operating in the Radio Access Network (RAN) industry. As the RAN is an essential part of any mobile network, the O-RAN ALLIANCE’s mission is to re-shape the industry towards more intelligent, open, virtualized and fully interoperable mobile networks. The new O-RAN standards will enable a more competitive and vibrant RAN supplier ecosystem with faster innovation to improve user experience. O-RAN based mobile networks will at the same time improve the efficiency of RAN deployments as well as operations by the mobile operators. To achieve this, the O-RAN ALLIANCE publishes new RAN specifications, releases open software for the RAN, and supports its members in integration and testing of their implementations.
For more information please visit www.o-ran.org.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210623005961/en/
Contact information
O-RAN ALLIANCE PR Contact
Zbynek Dalecky
pr@o-ran.org
O-RAN ALLIANCE e.V.
Buschkauler Weg 27
53347 Alfter/Germany
About Business Wire
Business WireSubscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
HCLTech Reports FY24 Revenue of $13.3 Billion, up 5.4% YoY26.4.2024 22:06:00 CEST | Press release
HCLTech, a leading global technology company, today reported financial results for the fourth quarter and the full year ended March 31, 2024. The company reported full year revenue of $13.3 billion, up 5.4% YoY. Digital Services revenue grew by 5.3% (CC) and now contributes to 37.3% of IT Services revenue. HCLSoftware’s Annual Recurring Revenue came in at $1.02 billion. During FY24, the company won 73 large deals – 36 in Services and 37 in Software - that translated into TCV (new deal wins) of $9.76 billion, up 10% YoY. For the quarter, revenue came in at $3.43 billion, up 6% YoY. HCLTech won 21 large deals – 13 in Services and eight in Software, with a TCV of $2.29 billion during the quarter. In terms of geographies, Americas was the fastest growing region with 6.8% YoY (CC) growth followed by Europe, which grew by 5.5% YoY (CC). Industry vertical growth was led by Financial Services and Telecommunications, Media, Publishing & Entertainment. While Financial Services grew at 12.1% YoY
Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 18:03:00 CEST | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio
Vertex Announces European Commission Approval for KALYDECO ® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 17:43:00 CEST | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)
Suzano 2023 annual report on Form 20-F26.4.2024 17:22:00 CEST | Press release
Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/Contact information Hawthorn Advisors suzano@hawthornadvisors.com
Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer26.4.2024 14:30:00 CEST | Press release
Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (mCRC). The European Commission (EC) will consider the CHMP positive opinion when determining the potential marketing authorization for fruquintinib for mCRC throughout the European Union (EU), Norway, Liechtenstein and Iceland. If approved, fruquintinib will be the first and only selective inhibitor of all three VEGF receptors approved in the EU for previously treated mCRC.1,2 “People living with metastatic colorectal cancer in the European Union currently have limited treatment options, which can lead to poor outcomes. With this positive opinion for fruquintinib, we are one step closer to potentially offering patients a new
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom